Asahi Kasei Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Asahi Kasei Corporation
Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?
The Israeli biotech announced disappointing Phase II/III data for opaganib while expanding its Phase II/III RHB-107 study. Pharming unveiled promising data from a company-sponsored study, but an imbalance in an investigator-led study confounded results, while CalciMedica built on the case for its drug as a treatment for COVID-19 pneumonia.
ARM counts $14.1bn in fundraising in the first half of 2021, up 35% from mid-year 2020. Also, Chinese mRNA players Abogen raises a $700m series C venture capital round, Pfizer prices a $1bn sustainability bond and while IPOs slow in the US, China and South Korea see new first-time offerings.
Korean bioventure ViGenCell successfully completes an IPO on the Kosdaq market with strong subscription rates from investors, reflecting the continued keen interest in biopharma shares in South Korea this year.
- Medical Devices
- Other Names / Subsidiaries
- Advanced Circulatory Systems, Inc.
- Artisan Pharmaceuticals
- Asahi Kasei Holdings US, Inc.
- Asahi Kasei Pharma America Corp. (AKP America)
- Cardiac Science Corporation
- Golden Hour Data Systems, Inc.
- Kyma Medical Technologies, Ltd.
- Mobilize RRS LLC.
- TherOx, Inc.
- Veloxis Pharmaceuticals Inc.
- ZOLL Medical Corporation